Management of AML with FLT3 Mutation

Current Treatment Analysis

The combination of azacitidine and venetoclax has been used for 7 days, with midostaurin added, which is appropriate for a patient with AML harboring FLT3-TKD mutation, according to the National Comprehensive Cancer Network 1, 2
Discontinuation of sulfasalazine and steroids was necessary to prioritize AML treatment and avoid potential drug interactions, as recommended by the Annals of Oncology and Blood 3, 4

Midostaurin is recommended to be added to standard treatment regimens for FLT3-mutated AML, as it specifically targets the FLT3 mutation, according to the National Comprehensive Cancer Network 1, 2
The combination of azacitidine and FLT3 inhibitors has demonstrated efficacy in FLT3-positive AML, with reported CR/CRi rates of 67% in clinical studies, as per the National Comprehensive Cancer Network 5
For pediatric patients with AML, intensive anthracycline and cytarabine-based therapy is typically recommended, but the current regimen may be appropriate considering the patient's specific molecular profile, according to Blood 6

Close monitoring for differentiation syndrome is essential, particularly with the use of FLT3 inhibitors, which may be managed with corticosteroids and hydroxyurea, as recommended by the National Comprehensive Cancer Network 5
Regular assessment for hyperleukocytosis is important, as it can lead to hemorrhagic events, tumor lysis syndrome, and infections, according to Blood 4

The patient's JIA symptoms had improved with sulfasalazine after failing methotrexate and hydroxychloroquine, as reported in the Journal of Internal Medicine 7
Currently, JIA management should be deferred while focusing on AML treatment, as the leukemia poses the more immediate life-threatening condition, according to the National Comprehensive Cancer Network 8
After achieving remission of AML, JIA treatment can be reconsidered, potentially with agents that have less bone marrow suppression, as per Blood 4
The development of pancytopenia while on JIA treatment was likely related to the underlying AML rather than medication toxicity, according to Blood 6

Bone marrow evaluation should be performed 14-21 days after starting therapy to assess response, as recommended by the National Comprehensive Cancer Network 9
For patients achieving complete remission, consideration for allogeneic stem cell transplantation should be evaluated, especially given the high-risk molecular features, according to the National Comprehensive Cancer Network 8
If the patient responds well to the current regimen, maintenance therapy with midostaurin could be considered, although its benefit after chemotherapy consolidation remains unclear, as per the Annals of Oncology 3

If the patient fails to respond to the current regimen, alternative options include intensive induction chemotherapy with cytarabine and anthracycline, clinical trial enrollment, or consideration of allogeneic stem cell transplantation, as recommended by Blood and the National Comprehensive Cancer Network 5, 6, 8